Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countries
- 12 November 1999
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 18 (7-8), 736-742
- https://doi.org/10.1016/s0264-410x(99)00269-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued useThe Lancet, 1997
- Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infantsThe Lancet, 1997
- Prospects for the use of new vaccines in developing countries: cost is not the only impedimentVaccine, 1996
- Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infectionsThe Pediatric Infectious Disease Journal, 1996
- A framework for the evaluation of vaccines for use in the expanded programme on immunizationVaccine, 1994
- The Efficacy in Navajo Infants of a Conjugate Vaccine Consisting ofHaemophilus influenzaeType b Polysaccharide andNeisseria meningitidisOuter-Membrane Protein ComplexNew England Journal of Medicine, 1991
- Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 childrenThe Pediatric Infectious Disease Journal, 1991
- A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, ChileThe Pediatric Infectious Disease Journal, 1990
- HAEMOPHILUS INFLUENZAE TYPE b DISEASE IN AN ARAB GULF STATEThe Pediatric Infectious Disease Journal, 1989
- Efficacy ofHaemophilus IinfluenzaeType b Polysaccharide–Diphtheria Toxoid Conjugate Vaccine in InfancyNew England Journal of Medicine, 1987